Below are current clinical trials.26 studies in Inflammatory bowel disease (IBD)
(open studies only).
Filter this list of studies by location, status and more.
The purpose of the study is to:
- Map and compare the neoplasia-associated epigenetic field in IBD-CRN, sporadic CRN and controls.
- Measure sensitivity of DNA methylation for the detection of synchronous IBD-CRN as a complement or alternative to histologic diagnosis of dysplasia on random biopsies.
- Measure the density and types of lymphocytes infiltrating IBD-CRN tumors, sporadic tumors and the epigenetic field.
The purpose of this study is to observe the long-term safety of filgotinib in adults who have ulcerative colitis, and have completed or met specific effectiveness criteria in a prior Gilead-sponsored filgotinib treatment study.
The focus of this study is to retrospectively examine the patterns of use of biological agents and risk factors for discontinuation of these agents in pediatric Crohn’s disease (CD) and ulcerative colitis (UC) within the ICN network. This will be a retrospective longitudinal observational cohort study. The study population for the first portion of the study (Aim 1a below) will be all CD and UC patients in ICN who were diagnosed with IBD prior to age 18. This population will be queried for biologic use prior to age 18. The study population for the remainder of the study will be all CD and UC patients in ICN who received their first biologic medication before 18 years of age and who initiated therapy with the first biologic medication after registration in ICN.
This phase III, double blind, placebo-controlled, multicenter study will investigate the efficacy and safety of etrolizumab during induction and maintenance of remission in participants with moderately to severely active ulcerative colitis (UC) who are refractory to or intolerant of TNF inhibitors.
The objective of this study is to compare the safety, tolerance and efficacy of BLI800 to a PEG based preparation prior to colonoscopy in adolescent patients.
The purpose of this study is to observe the long-term safety of filgotinib in adults who have either completed or met the specific effectiveness criteria in a prior Gilead-sponsored filgotinib treatment study for Crohn's disease.
The primary objectives of this study are to evaluate the safety and efficacy of filgotinib during induction and maintenance treatment of moderately to severely active Crohn's disease (CD) in participants who are biologic-naive and biologic-experienced.
Participants who complete the study, or do not meet protocol response or remission criteria at Week 10 will have the option to enter a separate long-term extension (LTE) study (Gilead Study GS-US-419-3896).
The aim of this study is to test the validity of the current question database in a large cohort of children with Inflammatory Bowel Disease (IBD) in several pediatric gastroenterology centers.
The primary objective of this study is to observe the long-term safety of filgotinib in adults who have completed or met protocol specified efficacy discontinuation criteria in a prior Gilead-sponsored filgotinib treatment study in Crohn's disease (CD).
The purpose of the study is to compare the addition of structured psychosocial care versus standard medical care alone for the treatment of adult patients who have inflammatory bowel disease
Aug. 09, 2017
- Goldman L, et al., eds. Inflammatory bowel disease. In: Goldman-Cecil Medicine. 25th ed. Philadelphia, Pa.: Saunders Elsevier; 2016. https://www.clinicalkey.com. Accessed May 10, 2017.
- What is inflammatory bowel disease (IBD)? Centers for Disease Control and Prevention. https://www.cdc.gov/ibd/what-is-IBD.htm. Accessed July 7, 2017.
- Overview of inflammatory bowel disease. The Merck Manual for Health Care Professionals. http://www.merckmanuals.com/professional/gastrointestinal-disorders/inflammatory-bowel-disease-ibd/overview-of-inflammatory-bowel-disease. Accessed July 7, 2017.
- IBD overview. American College of Gastroenterology. http://patients.gi.org/topics/inflammatory-bowel-disease/#tabs2. Accessed July 7, 2017.
- IBD 101: What is inflammatory bowel disease? American Gastroenterological Association. http://www.gastro.org/info_for_patients/ibd-101-what-is-inflammatory-bowel-disease. Accessed July 7, 2017.
- Peppercorn MA, et al. Clinical manifestations, diagnosis, and prognosis of ulcerative colitis in adults. https://www.uptodate.com/contents/search. Accessed July 7, 2017.
- What is colorectal cancer screening? Centers for Disease Control and Prevention. https://www.cdc.gov/cancer/colorectal/basic_info/screening/. Accessed May 12, 2017.
- Feldman M, et al. Ulcerative colitis. In: Sleisenger and Fordtran's Gastrointestinal and Liver Disease: Pathophysiology, Diagnosis, Management. 10th ed. Philadelphia, Pa.: Saunders Elsevier; 2016. https://www.clinicalkey.com. Accessed June 20, 2017.
- Inflammatory bowel disease. U.S. Department of Health and Human Services. https://www.womenshealth.gov/a-z-topics/inflammatory-bowel-disease. Accessed July 7, 2017.
- The role of endoscopy in inflammatory bowel disease. Gastrointestinal Endoscopy. 2015;81:1101.
- Ulcerative colitis. National Institute of Diabetes and Digestive and Kidney Diseases. https://www.niddk.nih.gov/health-information/digestive-diseases/ulcerative-colitis. Accessed June 20, 2017.
- Diet, nutrition, and inflammatory bowel disease. Crohn's & Colitis Foundation of America. http://www.crohnscolitisfoundation.org/. Accessed May 15, 2017.
- Inflammatory bowel disease. Natural Medicines. https://naturalmedicines.therapeuticresearch.com. Accessed June 21, 2017.
- Complementary and alternative medicine (CAM). Crohn's & Colitis Foundation. http://www.crohnscolitisfoundation.org/resources/complementary-alternative.html. Accessed June 21, 2017.
- Yanai H, et al. Complementary therapies in inflammatory bowel diseases. Current Gastroenterology Reports. 2016;18:62.
- Brown A. Allscripts EPSi. Mayo Clinic, Rochester, Minn. July 17, 2017.
- Rajan E (expert opinion). Mayo Clinic, Rochester, Minn. July 14, 2017.
Inflammatory bowel disease (IBD)